Comparative Pharmacology
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus POLYCILLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus POLYCILLIN N.
NALLPEN IN PLASTIC CONTAINER vs POLYCILLIN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, and activating autolytic enzymes. It is bactericidal against susceptible organisms.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
1-2 g IV/IM every 4-6 hours
None Documented
None Documented
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
Terminal elimination half-life: 0.5-1 hour (normal renal function); increases to 7-10 hours in anuria. Prolonged in neonates (2-4 hours).
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: ~20% excreted in bile and feces. Small amount metabolized to penicilloic acid.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic